A study evaluating efficacy of 18F-PI2620 in detecting Tau pathology in aging and throughout the spectrum of Alzheimer's disease (AD)
Latest Information Update: 05 Oct 2018
Price :
$35 *
At a glance
- Drugs PI 2620 (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use
- 05 Oct 2018 New trial record
- 31 Aug 2018 Results presented at the 48th Annual Meeting of the International Continence Society